Clinical trial NCT01407393: Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Official title: Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Overweight and Obesity
Keywords: overweight
obesity
weight loss
body fat
waste cirumference
satiety
appetite
Lead sponsor: InQpharm Group
Sponsor class: INDUSTRY
First posted: 2011-08-02
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Glucosanol™, the medical device to be investigated contains a proprietary plant extract that is a natural inhibitor of alpha-amylase and can reduce starch digestion.

The rationale for this study is to confirm that Glucosanol™ ingestion will reduce body weight. A double-blind, randomized, placebo-controlled design has been chosen to assess the efficacy and safety of Glucosanol™ in subjects who are overweight and mildly obese.

Detailed description: Preparations that reduce absorption of calories from dietary carbohydrates could be decisively meaningful for the regulation of bodyweight or obesity. Hence, Glucosanol™ may be used as a tool for the treatment of obesity and weight management through reduced carbohydrate absorption.

The rationale for this study is to confirm that Glucosanol™ ingestion will reduce body weight. A double-blind, randomized, placebo-controlled design has been chosen to assess the efficacy and safety of Glucosanol™ in subjects who are overweight and mildly obese.

The specific hypotheses to be accepted or rejected by statistical data from the clinical investigation are beneficial effects of the device on weight loss (kg) and body fat content.

Eligibility criteria: Inclusion Criteria:

* Age 18 to 60 years
* BMI between 25 and 35
* Expressed desire for weight loss
* Accustomed to 3 main meals/day
* Consistent and stable body weight 3 months prior to study enrolment
* Commitment to avoid the use of other weight loss products during study
* Commitment to adhere to diet recommendation
* Females' agreement to use appropriate birth control methods during the active study period
* Subject declares in writing his/her consent to participate, understands requirements of the study and is willing to comply

Exclusion Criteria:

* Known sensitivity to the ingredients of the device
* History of Diabetes mellitus
* Fasting blood glucose \>7 mmol/L
* History or clinical signs of endocrine disorders which may influence body weight (e.g., Cushing's disease, thyroid gland disorders)
* Clinically relevant excursions of safety parameter
* Current use of anti-depressants
* Presence of acute or chronic gastrointestinal disease (e.g., IBD, coeliac disease. pancreatitis)
* Uncontrolled hypertension (\>160/110 mm Hg)
* Stenosis in the GI tract
* Bariatric surgery
* Abdominal surgery within the last 6 months prior to enrollment
* History of eating disorders such as bulimia, anorexia nervosa within the past 12 months
* Other serious organ or systemic diseases such as cancer
* Any medication that could influence GI functions such as antibiotics, laxatives, opioids, glucocorticoids, anticholinergics, or antidiarrheals (e.g., loperamide; must have stopped 1 months before study start)
* Pregnancy or nursing
* Any medication or use of products for the treatment of obesity
* More than 3 hours strenuous sport activity per week
* History of abuse of drugs, alcohol or medication
* Smoking cessation within 6 months prior to enrolment
* Inability to comply due to language difficulties
* Participation in similar studies or weight loss programs within 3 months prior to enrolment
* Participation in other studies within 4 weeks prior to enrollment

Primary outcomes:
measure: weight loss
timeFrame: 12 weeks
Secondary outcomes:
measure: Proportion body weight
timeFrame: 12 weeks
measure: waist circumference
timeFrame: 12 weeks
measure: hip circumference
timeFrame: 12 weeks
measure: waist-hip-ratio
timeFrame: 12 weeks
measure: BMI
timeFrame: 12 weeks
measure: body fat
timeFrame: 12 weeks
measure: hunger
timeFrame: 12 weeks
measure: Global evaluation of feeling of satiety
timeFrame: 12 weeks
measure: Global evaluation of the efficacy
timeFrame: 12 weeks
measure: Global evaluation of safety
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Barbara Grube
Study officials:
name: Barbara Grube, MD
role: PRINCIPAL_INVESTIGATOR
References: